We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+12.96%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$121M
AUM Growth
+$9.54M
Cap. Flow
-$73.4K
Cap. Flow %
-0.06%
Top 10 Hldgs %
83.4%
Holding
29
New
2
Increased
1
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
LBRX
LB Pharmaceuticals
LBRX
+$7.63M
2
CELC icon
Celcuity
CELC
+$3.09M
3
INSM icon
Insmed
INSM
+$1.01M

Top Sells

Rank Stock Value
1
OCS icon
Oculis Holding
OCS
+$4.34M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$2.96M
3
LAB icon
Standard BioTools
LAB
+$2.41M
4
REPL icon
Replimune Group
REPL
+$619K
5
INCY icon
Incyte
INCY
+$527K

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Technology 2.51%
3 Industrials 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVMN
1
Evommune Inc
EVMN
$415M
$33.1M 27.32%
1,441,032
– –
MPLT
2
MapLight Therapeutics
MPLT
$1.63B
$19.7M 16.28%
971,253
– –
LBRX
3
LB Pharmaceuticals
LBRX
$886M
$15.6M 12.82%
630,657
+330,657
+110% +$7.63M
OCS icon
4
Oculis Holding
OCS
$708M
$9.33M 7.69%
350,745
-163,957
-32% -$4.34M
INCY icon
5
Incyte
INCY
$23.1B
$5.06M 4.17%
53,742
-5,280
-9% -$527K
ONC
6
BeOne Medicines Ltd
ONC
$32.2B
$4.67M 3.85%
15,722
– –
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.17B
$4.27M 3.52%
49,120
– –
CELC icon
8
Celcuity
CELC
$4.29B
$3.23M 2.66%
+28,300
New +$3.09M
ASND icon
9
Ascendis Pharma A/S
ASND
$16.5B
$3.11M 2.57%
13,600
– –
PCOR icon
10
Procore
PCOR
$6.98B
$3.04M 2.51%
53,299
– –
MDGL icon
11
Madrigal Pharmaceuticals
MDGL
$12.4B
$2.97M 2.45%
5,672
-6,200
-52% -$2.96M
KYMR icon
12
Kymera Therapeutics
KYMR
$9.14B
$2.57M 2.12%
30,875
– –
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$4.3B
$2.29M 1.89%
102,984
– –
HELP
14
Cybin Inc
HELP
$441M
$2.21M 1.82%
460,000
– –
ARGX icon
15
argenx
ARGX
$52.9B
$2.04M 1.69%
2,800
– –
RVMD icon
16
Revolution Medicines
RVMD
$38.4B
$1.87M 1.54%
19,253
– –
RXRX icon
17
Recursion Pharmaceuticals
RXRX
$1.53B
$1.83M 1.51%
595,287
– –
INSM icon
18
Insmed
INSM
$23.2B
$1.08M 0.89%
+6,580
New +$1.01M
ETHA
19
iShares Ethereum Trust ETF
ETHA
$5.35B
$800K 0.66%
50,549
– –
HRMY icon
20
Harmony Biosciences
HRMY
$1.94B
$758K 0.62%
27,049
– –
TRDA icon
21
Entrada Therapeutics
TRDA
$246M
$619K 0.51%
49,082
– –
IBIT icon
22
iShares Bitcoin Trust
IBIT
$47.9B
$613K 0.51%
15,968
– –
RANI icon
23
Rani Therapeutics
RANI
$77.1M
$363K 0.3%
493,584
– –
BOLT icon
24
Bolt Biotherapeutics
BOLT
$8.59M
$118K 0.1%
29,250
-29,097
-50% -$152K
BCYC
25
Bicycle Therapeutics
BCYC
$290M
– –
-68,943
Closed -$488K
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $121M AUM
CIM
Chapman Investment Management San Anselmo, California $121M AUM 1.51% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
FF
Farnam Financial Phoenix, Arizona $122M AUM 12.88% 1-Year Est. Return

Nan Fung Group Holdings's Q1 2026 Portfolio in Review

As of Q1 2026, Nan Fung Group Holdings held 29 positions worth $121M, up 8.5% from $112M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Nan Fung Group Holdings's Q1 2026 filing shows 2 new, 1 increased, 4 reduced and 5 closed positions. Its largest new stake was Celcuity: 28,300 shares worth $3.23M. The largest sale was Oculis Holding, an estimated $4.34M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Technology and Industrials.

  • Nan Fung Group Holdings's largest Q1 2026 buy was Celcuity: 28,300 shares worth $3.23M.
  • Nan Fung Group Holdings added most to LB Pharmaceuticals in Q1 2026, an estimated $7.63M increase.
  • Nan Fung Group Holdings's biggest Q1 2026 reduction was Oculis Holding, cutting an estimated $4.34M.
  • Nan Fung Group Holdings fully exited Standard BioTools in Q1 2026, selling an estimated $2.41M.
  • Nan Fung Group Holdings's ten largest holdings make up 83% of its $121M portfolio in Q1 2026.
  • Nan Fung Group Holdings opened 2 new positions and closed 5 in Q1 2026.
  • Nan Fung Group Holdings's portfolio value rose 8.5% quarter-over-quarter to $121M.

Based on Nan Fung Group Holdings's 13F filing for Q1 2026, filed 14 May 2026.